DB:ET82

Stock Analysis Report

Executive Summary

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Aeterna Zentaris's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ET82's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.1%

ET82

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-88.9%

ET82

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: ET82 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: ET82 underperformed the German Market which returned -17.7% over the past year.


Shareholder returns

ET82IndustryMarket
7 Day10.1%11.2%7.3%
30 Day-36.0%-5.3%-17.9%
90 Day-32.6%-21.9%-25.8%
1 Year-88.9%-88.9%-4.9%-5.1%-15.1%-17.7%
3 Year-83.4%-83.4%17.7%16.5%-18.7%-25.6%
5 Year-99.0%-99.0%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Aeterna Zentaris's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aeterna Zentaris undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Aeterna Zentaris is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Aeterna Zentaris has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Aeterna Zentaris forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aeterna Zentaris has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Aeterna Zentaris performed over the past 5 years?

31.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ET82 is currently unprofitable.

Growing Profit Margin: ET82 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ET82 is unprofitable, but has reduced losses over the past 5 years at a rate of 31.9% per year.

Accelerating Growth: Unable to compare ET82's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ET82 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: ET82's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Aeterna Zentaris's financial position?


Financial Position Analysis

Short Term Liabilities: ET82 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ET82 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ET82 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ET82's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: ET82 has a low level of unsold assets or inventory.

Debt Coverage by Assets: ET82 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ET82 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ET82 has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.4% each year.


Next Steps

Dividend

What is Aeterna Zentaris's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ET82's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ET82's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ET82's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ET82's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ET82's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Klaus Paulini

0.42

Tenure

Dr. Klaus Paulin has been President, Chief Executive Officer and Director of Aeterna Zentaris Inc., since October 4, 2019. Dr. Paulini had been as Managing Director of German subsidiary at Aeterna Zentaris ...


Leadership Team

NamePositionTenureCompensationOwnership
Leslie Auld
Senior VP & CFO1.5yrsUS$233.94kno data
Klaus Paulini
President0.42yrno datano data
Nicola Ammer
Chief Medical Officer & VP of Clinical Development2yrsno datano data
Olaf Althaus
1.75yrsno datano data
Eckhard Guenther
Managing Director of Aeterna Zentaris GmbH0.17yrno datano data
Amélie Métivier
Assistant Secretary10.92yrsno datano data

1.6yrs

Average Tenure

Experienced Management: ET82's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Klaus Paulini
President0.42yrno datano data
Gilles Gagnon
Director0.17yrUS$980.55kno data
Gérard Limoges
Independent Director15.25yrsUS$108.67k0.0051% $568.6
Hartmut Michel
Member of the Scientific Advisory Boardno datano datano data
Marcel Verheij
Member of the Scientific Advisory Boardno datano datano data
René Frydman
Member of the Scientific Advisory Boardno datano datano data
Alan DeCherney
Member of the Scientific Advisory Boardno datano datano data
Klaus Diedrich
Member of the Scientific Advisory Boardno datano datano data
Frans Debruyne
Member of the Scientific Advisory Boardno datano datano data
Carolyn Egbert
Chair of the Board3.83yrsUS$218.67k0.0082% $910.9

2.1yrs

Average Tenure

Experienced Board: ET82's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Aeterna Zentaris Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aeterna Zentaris Inc.
  • Ticker: ET82
  • Exchange: DB
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$17.397m
  • Listing Market Cap: CA$11.149m
  • Shares outstanding: 23.51m
  • Website: https://www.zentaris.com

Number of Employees


Location

  • Aeterna Zentaris Inc.
  • 315 Sigma Drive
  • Suite 302D
  • Summerville
  • South Carolina
  • 29486
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AEZSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDDec 1995
AEZSTSX (The Toronto Stock Exchange)YesCommon SharesCACADDec 1995
ET82DB (Deutsche Boerse AG)YesCommon SharesDEEURDec 1995
0UGBLSE (London Stock Exchange)YesCommon SharesGBCADDec 1995

Biography

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 22:52
End of Day Share Price2020/03/30 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.